DanielJMaMD
Radiation Oncology • Rochester, MNCentral Nervous System Cancer, Head & Neck
Assistant Professor, Radiation Oncology, Mayo Medical School
Dr. Ma is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Radiation Oncology, 2007 - 2011
St Elizabeth's Medical Center/Lemuel Shattuck HospitalInternship, Transitional Year, 2006 - 2007- Washington University in St. Louis School of MedicineClass of 2006
Certifications & Licensure
MN State Medical License 2011 - 2025
WI State Medical License 2013 - 2021- American Board of Radiology Radiation Oncology
Clinical Trials
- Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer Start of enrollment: 2013 Sep 04
- Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC Start of enrollment: 2020 Nov 19
Roles: Contact
Publications & Presentations
PubMed
- 463 citationsEstimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)Paul W. Sperduto, T. Jonathan Yang, Kathryn Beal, Hubert Y. Pan, Paul D. Brown
JAMA Oncology. 2017-06-01 - 118 citationsPhase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus–Associated Oropharynx Squamous Cell CarcinomaDaniel J. Ma, Katharine A. Price, Eric J. Moore, Samir H. Patel, Michael L. Hinni
Journal of Clinical Oncology. 2019-06-04 - 17 citationsFactors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for O...Shruthi Vaidhyanathan, Brynna Wilken-Resman, Daniel J. Ma, Karen E. Parrish, Rajendar K. Mittapalli
The Journal of Pharmacology and Experimental Therapeutics. 2016-02-01
Authored Content
- The Debate Surrounding Treatment De-Escalation for HPV-Positive Oropharynx CancerFebruary 2018
- The Debate Surrounding Treatment De-Escalation for HPV-Positive Oropharynx CancerFebruary 2018
- The Debate Surrounding Treatment De-Escalation for HPV-Positive Oropharynx CancerFebruary 2018
- The Debate Surrounding Treatment De-Escalation for HPV-Positive Oropharynx CancerFebruary 2018
- The Debate Surrounding Treatment De-Escalation for HPV-Positive Oropharynx CancerFebruary 2018
- Join now to see all
Press Mentions
Mayo Clinic Q&A Podcast: Head and Neck Cancers Are Becoming Increasingly CommonApril 19th, 2021
Mayo Clinic Researchers to Present Findings at ASTRO Annual MeetingSeptember 18th, 2019
Dose De-Escalation in Adjuvant Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell CarcinomaJune 19th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
